Trade Amgen - AMGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.48 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.35 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 333.84 |
| Open | 336.8 |
| 1-Year Change | 43.33% |
| Day's Range | 333.45 - 337.95 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 333.69 | -1.26 | -0.38% | 334.95 | 346.56 | 332.95 |
| Jul 24, 2024 | 335.50 | 3.54 | 1.07% | 331.96 | 336.88 | 329.96 |
| Jul 23, 2024 | 333.05 | -0.60 | -0.18% | 333.65 | 336.26 | 329.92 |
| Jul 22, 2024 | 335.74 | 3.29 | 0.99% | 332.45 | 336.84 | 332.45 |
| Jul 19, 2024 | 331.19 | -2.38 | -0.71% | 333.57 | 333.57 | 328.18 |
| Jul 18, 2024 | 330.78 | -3.17 | -0.95% | 333.95 | 338.62 | 330.44 |
| Jul 17, 2024 | 335.61 | 6.62 | 2.01% | 328.99 | 336.14 | 327.04 |
| Jul 16, 2024 | 332.98 | 3.33 | 1.01% | 329.65 | 335.51 | 327.95 |
| Jul 15, 2024 | 330.16 | -1.28 | -0.39% | 331.44 | 332.11 | 327.49 |
| Jul 12, 2024 | 330.71 | 4.46 | 1.37% | 326.25 | 333.65 | 325.63 |
| Jul 11, 2024 | 324.97 | 4.27 | 1.33% | 320.70 | 327.64 | 319.57 |
| Jul 10, 2024 | 321.60 | 5.18 | 1.64% | 316.42 | 322.71 | 314.12 |
| Jul 9, 2024 | 315.54 | 4.34 | 1.39% | 311.20 | 315.94 | 307.61 |
| Jul 8, 2024 | 311.30 | 0.13 | 0.04% | 311.17 | 315.24 | 310.46 |
| Jul 5, 2024 | 310.61 | 0.61 | 0.20% | 310.00 | 313.28 | 308.49 |
| Jul 3, 2024 | 309.04 | -1.33 | -0.43% | 310.37 | 312.11 | 305.95 |
| Jul 2, 2024 | 310.63 | 0.48 | 0.15% | 310.15 | 312.13 | 307.03 |
| Jul 1, 2024 | 310.76 | -1.64 | -0.52% | 312.40 | 318.87 | 310.11 |
| Jun 28, 2024 | 312.37 | 0.04 | 0.01% | 312.33 | 316.37 | 309.95 |
| Jun 27, 2024 | 313.46 | 3.30 | 1.06% | 310.16 | 316.20 | 310.16 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Amgen Company profile
About Amgen, Inc.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).
Equity composition
Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).
| Industry: | Pharmaceuticals (NEC) |
One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com